Gofex Drug Interactions

Acetylsalicylic acid: Concomitant administration of ibuprofen and Acetylsalicylic acid is not generally recommended because of the potential of increased adverse effects. Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see Pharmacology: Pharmacodynamics under Actions).
Diuretics: The efficacy of furosemide and thiazide diuretics can be decreased, probably due to sodium retention related to an inhibition of prostaglandin synthesis in the kidneys.
Corticosteroid: Increase risk of gastrointestinal ulceration or bleeding (see Precautions).
Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see Precautions).
Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see Precautions).
Anti-hypertensives agents: Ibuprofen may diminish the effects of antihypertensives.
Consequently, the concomitant use of NSAIDs and ACE Inhibitors or beta-blocking agents may be associated with a risk of acute renal failure.
Digoxin, phenytoin, lithium: In the literature individual cases of increase plasma levels of digoxin, phenytoin and lithium due to ibuprofen have been described.
Other non-steroid anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 selective inhibitors: Ibuprofen (like other NSAIDS) should be used with caution in combination with acetylsalicylic acid or other NSAIDs and systemic corticosteroids: This may increase the risk of adverse drug reactions in the gastrointestinal tract.
Methotrexate: Ibuprofen can increase methotrexate plasma levels.
Zidovudine: Concurrent treatment of zidovudine and ibuprofen can increase the risk of haemarthrosis and haematoma in HIV (+) haemophilic patients.
Tacrolimus: Concurrent use of ibuprofen and tacrolimus can increase the risk of nephrotoxicity, due to the reduction of the renal prostaglandins synthesis.
Hypoglycaemics agent: Ibuprofen increases hypoglycemic effects of oral hypoglycemic agents and insulin. It may be necessary to adjust the dosage.
Cyclosporine: Concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) may result in increased risk of cyclosporine nephrotoxicity effect.
Voriconazole or Fluconazole: Concurrent use of ibuprofen may result in increased ibuprofen exposure and plasma concentration.
Mifepristone: Concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) may result in increased exposure to the NSAID. A decrease in the efficacy of mifepristone can theoretically occur due to the antiprostaglandin properties of NSAIDs. Studies on the effect of single or repeated ibuprofen administration starting on the day prostaglandin administration (or as needed) did not find evidence of an adverse influence on the action of mifepristone, nor or the overall clinical efficacy of the pregnancy termination protocol.
Quinolone antibiotics: Concurrent use of non-steroidal use of non-steroidal anti-inflammatory drugs (NSAIDs) may result in an increased risk of seizures.
Herbal Extract: Gingko biloba may potentiate the risk of bleeding with NSAIDS.
Aminoglycosides: NSAIDs may decrease the excretion of aminoglycosides.
Interactions with diagnostic test results: Bleeding time (may prolong bleeding time until 1 day after discontinuation of therapy).
Serum glucose concentration (may decrease).
Creatinine Clearance (may decrease).
Haematocrit or haemoglobin (may decrease).
BUN, serum creatinine concentration and kaliemia (may increase).
Liver function test (may occur elevation of transaminases).